{"name":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 62","medgen_id":"C5394083","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032919\"}","{\"db\":\"OMIM\",\"id\":\"618793\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618793\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, AUTOSOMAL DOMINANT 62\"}","{\"db\":\"OMIM\",\"id\":\"602887.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602887.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602887.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602887.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602887.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"602887.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618793\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618793\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["MENTAL RETARDATION, AUTOSOMAL DOMINANT 62"],"type":"Disease","attribute_content":[],"symbol":"MRD62","id":"43719"}
{"name":"C4a deficiency","medgen_id":"C3280642","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0045043\",\"type\":\"primary\"}","{\"db\":\"OMIM\",\"id\":\"614380\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Complement+component+4a+deficiency/8026\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Complement component 4a deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0045043\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Decreased serum complement C4a\"}","{\"db\":\"OMIM\",\"id\":\"614380\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Complement component 4a deficiency","Decreased serum complement C4a"],"type":"Disease","attribute_content":[],"symbol":"C4AD","id":"12744"}
{"name":"Periventricular gray matter heterotopia","medgen_id":"CN212548","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002272\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007165\",\"type\":\"primary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007165\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Periventricular neuronal heterotopia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007165\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Subependymal gray matter heterotopia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007165\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Subependymal neuronal heterotopia\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007165\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Periventricular neuronal heterotopia","Subependymal gray matter heterotopia","Subependymal neuronal heterotopia"],"type":"Finding","attribute_content":[],"id":"26027"}
{"name":"Type III lissencephaly","medgen_id":"CN225412","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0045028\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0015148\"}","{\"db\":\"Orphanet\",\"id\":\"102011\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0015148\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Lissencephaly type 3\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0045028\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Lissencephaly type 3"],"type":"Finding","attribute_content":[],"id":"32670"}
{"name":"Clear cell carcinoma of kidney","medgen_id":"C0279702","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006770\",\"type\":\"primary\"}","{\"db\":\"Orphanet\",\"id\":\"319276\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006770\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Clear cell renal cell carcinoma\"}","{\"db\":\"SNOMED CT\",\"id\":\"254915003\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Clear cell RCC","Clear cell renal cell carcinoma","Clear-cell metastatic renal cell carcinoma (subtype)","Cystic-multilocular variant","Renal cell carcinoma, clear cell, somatic"],"type":"Disease","attribute_content":[],"id":"18267"}
{"name":"Gonadotropin deficiency","medgen_id":"C4552011","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0015890\"}","{\"db\":\"Orphanet\",\"id\":\"181387\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008213\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Pituitary gonadotropin deficiency\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0008213\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Pituitary gonadotropin deficiency"],"type":"Finding","attribute_content":[],"id":"38851"}
{"name":"Atypical chronic myeloid leukemia","medgen_id":"C1292772","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0020312\"}","{\"db\":\"Orphanet\",\"id\":\"98824\"}","{\"db\":\"NCBI for submitter\",\"id\":\"13-00656\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608232\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":[],"type":"Disease","attribute_content":[],"symbol":"ACML","id":"17744"}
{"name":"Renal cell carcinoma, nonpapillary","medgen_id":"CN074294","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007763\"}","{\"db\":\"OMIM\",\"id\":\"144700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"422526\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+cell+carcinoma%2C+nonpapillary/9213\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"144700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":["Hereditary cancer syndrome"],"alternate_names":[],"type":"Disease","attribute_content":[],"symbol":"RCC","id":"15944"}
{"name":"MYASTHENIC SYNDROME, CONGENITAL, 23, PRESYNAPTIC","medgen_id":"C4748678","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032596\"}","{\"db\":\"OMIM\",\"id\":\"618197\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"190315.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"190315.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618197\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618197\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":[],"type":"Disease","attribute_content":[],"symbol":"CMS23","id":"40839"}
{"gard_id":"5506","name":"Vitreoretinopathy","medgen_id":"C0344290","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000655\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007773\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020248\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007773\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Vitreoretinal abnormality\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0000655\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Vitreoretinal degeneration\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5506\",\"ref_field\":\"gard_id\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007773\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Vitreoretinal abnormality","Vitreoretinal degeneration"],"type":"Finding","attribute_content":[],"id":"26394"}
{"name":"Dysautonomia","medgen_id":"C0013363","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002387\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002459\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0007310\",\"type\":\"secondary\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012332\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0044872\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0012332\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abnormal autonomic nervous system physiology\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002459\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Autonomic dysfunction\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0002459\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Abnormal autonomic nervous system physiology","Autonomic dysfunction"],"type":"Finding","attribute_content":[],"id":"23088"}
{"name":"Focal Segmental Glomerulosclerosis 10","medgen_id":"CN293575","xrefs":[],"alternate_symbols":[],"keywords":[],"alternate_names":[],"type":"Disease","attribute_content":[],"id":"33289"}
{"gard_id":"302","name":"Kostmann syndrome","medgen_id":"C5235141","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012548\"}","{\"db\":\"OMIM\",\"id\":\"610738\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"99749\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Severe+congenital+neutropenia+autosomal+recessive+3/6528\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Severe congenital neutropenia 3, autosomal recessive\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"302\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012548\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"770942003 \",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"610738\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Agranulocytosis infantile","Kostmann disease","Severe congenital neutropenia 3, autosomal recessive"],"type":"Disease","attribute_content":[],"symbol":"SCN3","id":"3465"}
{"name":"Clark-Baraitser syndrome","medgen_id":"C2931130","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010372\"}","{\"db\":\"OMIM\",\"id\":\"617752\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"300602\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BARAITSER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"617752\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"BARAITSER SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"617752\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, AUTOSOMAL DOMINANT 49\"}","{\"db\":\"OMIM\",\"id\":\"617752\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MRD49\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Clark-Baraitser+Syndrome/1653\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010372\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"617752\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["MRD49"],"keywords":[],"alternate_names":["BARAITSER SYNDROME","MENTAL RETARDATION, AUTOSOMAL DOMINANT 49","Mental retardation, tall stature, obesity, macrocephaly and typical facial features"],"type":"Disease","attribute_content":[],"symbol":"CLABARS","id":"38330"}
{"name":"Otospondylomegaepiphyseal dysplasia, autosomal recessive","medgen_id":"C4520892","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0044206\"}","{\"db\":\"OMIM\",\"id\":\"215150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"1427\"}","{\"db\":\"OMIM\",\"id\":\"215150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Chondrodystrophy with sensorineural deafness","Insley-Astley syndrome","Nance Sweeney chondrodysplasia","Nance-Insley syndrome"],"type":"Disease","attribute_content":[],"symbol":"OSMEDB","id":"5711"}
{"name":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 61","medgen_id":"C5231400","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032485\"}","{\"db\":\"OMIM\",\"id\":\"618009\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618009\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, AUTOSOMAL DOMINANT 61\"}","{\"db\":\"OMIM\",\"id\":\"603808.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603808.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603808.0003\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603808.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"603808.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618009\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618009\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["MENTAL RETARDATION, AUTOSOMAL DOMINANT 61"],"type":"Disease","attribute_content":[],"symbol":"MRD61","id":"43466"}
{"name":"Abducens nerve disorder","medgen_id":"C0271355","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011349\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020594\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0020594\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abducens nerve disease\"}","{\"db\":\"SNOMED CT\",\"id\":\" 398963001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abducens nerve weakness\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0011349\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Abducens palsy\"}","{\"db\":\"SNOMED CT\",\"id\":\" 398925009\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Abducens nerve disease","Abducens nerve weakness","Abducens palsy"],"type":"Finding","attribute_content":[],"id":"29250"}
{"name":"Malignant tumor of testis","content":"{\"Citation\":{\"@Abbrev\":\"NACB, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19042984\",\"@Source\":\"PubMed\"}}}","medgen_id":"C0153594","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010788\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0005447\"}","{\"db\":\"OMIM\",\"id\":\"603517.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"TESTICULAR TERATOMA, SOMATIC\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0010788\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Testicular cancer\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Malignant+tumor+of+testis/8785\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"363449006\",\"ref_field\":\"name\"}"],"alternate_symbols":[],"keywords":["Hereditary cancer syndrome"],"alternate_names":["Cancer of the testes","Primordial germ cell tumor susceptibility locus 1","TESTICULAR TERATOMA, SOMATIC","Testicular cancer","Testicular tumor, somatic"],"type":"Disease","attribute_content":[],"id":"8043"}
{"name":"INTELLECTUAL DEVELOPMENTAL DISORDER, AUTOSOMAL DOMINANT 60, WITH SEIZURES","medgen_id":"C5231497","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0032823\"}","{\"db\":\"OMIM\",\"id\":\"618587\",\"type\":\"MIM\"}","{\"db\":\"OMIM\",\"id\":\"618587\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, AUTOSOMAL DOMINANT 60, WITH SEIZURES\"}","{\"db\":\"OMIM\",\"id\":\"601024.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618587\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"618587\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["MENTAL RETARDATION, AUTOSOMAL DOMINANT 60, WITH SEIZURES"],"type":"Disease","attribute_content":[],"symbol":"MRD60","id":"42927"}
{"public_definition":"Menkes disease, occipital horn syndrome (OHS), and ATP7A-related distal motor neuropathy (DMN) are disorders of copper transport caused by pathogenic variants in ATP7A (encoding a copper-transporting ATPase). Infants with classic Menkes disease appear healthy until age two to three months, when loss of developmental milestones, hypotonia, seizures, and failure to thrive occur. The diagnosis is usually suspected when infants exhibit typical neurologic changes and concomitant characteristic changes of the hair (short, sparse, coarse, twisted, and often lightly pigmented). Temperature instability and hypoglycemia may be present in the neonatal period. Death usually occurs by age three years. OHS is characterized by \"occipital horns,\" distinctive wedge-shaped calcifications at the sites of attachment of the trapezius muscle and the sternocleidomastoid muscle to the occipital bone. Occipital horns may be clinically palpable or observed on skull radiographs. Individuals with OHS also have lax skin and joints, bladder diverticula, inguinal hernias, and vascular tortuosity. Intellect is normal or slightly reduced. ATP7A-related DMN, an adult-onset disorder resembling Charcot-Marie-Tooth disease, shares none of the clinical or biochemical abnormalities characteristic of Menkes disease or OHS.","gard_id":"4017","name":"Cutis laxa, X-linked","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301586\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1413\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21487442\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0268353","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010572\"}","{\"db\":\"OMIM\",\"id\":\"304150\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"198\"}","{\"db\":\"OMIM\",\"id\":\"304150\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"EDS IX\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010572\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Occipital horn syndrome\"}","{\"db\":\"OMIM\",\"id\":\"304150\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"EDS9\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4017\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Occipital+horn+syndrome/5286\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"59399004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1413\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"304150\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["EDS9"],"keywords":[],"alternate_names":["EDS IX","EDS IX (formerly)","Ehlers-Danlos syndrome, occipital horn type (formerly)","Occipital horn syndrome"],"type":"Disease","attribute_content":[],"symbol":"OHS","id":"3105"}
{"public_definition":"Menkes disease, occipital horn syndrome (OHS), and ATP7A-related distal motor neuropathy (DMN) are disorders of copper transport caused by pathogenic variants in ATP7A (encoding a copper-transporting ATPase). Infants with classic Menkes disease appear healthy until age two to three months, when loss of developmental milestones, hypotonia, seizures, and failure to thrive occur. The diagnosis is usually suspected when infants exhibit typical neurologic changes and concomitant characteristic changes of the hair (short, sparse, coarse, twisted, and often lightly pigmented). Temperature instability and hypoglycemia may be present in the neonatal period. Death usually occurs by age three years. OHS is characterized by \"occipital horns,\" distinctive wedge-shaped calcifications at the sites of attachment of the trapezius muscle and the sternocleidomastoid muscle to the occipital bone. Occipital horns may be clinically palpable or observed on skull radiographs. Individuals with OHS also have lax skin and joints, bladder diverticula, inguinal hernias, and vascular tortuosity. Intellect is normal or slightly reduced. ATP7A-related DMN, an adult-onset disorder resembling Charcot-Marie-Tooth disease, shares none of the clinical or biochemical abnormalities characteristic of Menkes disease or OHS.","name":"Distal spinal muscular atrophy, X-linked 3","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301586\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1413\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1845359","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010338\"}","{\"db\":\"OMIM\",\"id\":\"300489\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"139557\"}","{\"db\":\"OMIM\",\"id\":\"300489\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED RECESSIVE\"}","{\"db\":\"OMIM\",\"id\":\"300489\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"DSMAX\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Distal+spinal+muscular+atrophy%2C+x-linked+3/8276\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1413\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300489\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["DSMAX"],"keywords":[],"alternate_names":["SPINAL MUSCULAR ATROPHY, DISTAL, X-LINKED RECESSIVE"],"type":"Disease","attribute_content":[],"symbol":"SMAX3","id":"4176"}
{"public_definition":"Menkes disease, occipital horn syndrome (OHS), and ATP7A-related distal motor neuropathy (DMN) are disorders of copper transport caused by pathogenic variants in ATP7A (encoding a copper-transporting ATPase). Infants with classic Menkes disease appear healthy until age two to three months, when loss of developmental milestones, hypotonia, seizures, and failure to thrive occur. The diagnosis is usually suspected when infants exhibit typical neurologic changes and concomitant characteristic changes of the hair (short, sparse, coarse, twisted, and often lightly pigmented). Temperature instability and hypoglycemia may be present in the neonatal period. Death usually occurs by age three years. OHS is characterized by \"occipital horns,\" distinctive wedge-shaped calcifications at the sites of attachment of the trapezius muscle and the sternocleidomastoid muscle to the occipital bone. Occipital horns may be clinically palpable or observed on skull radiographs. Individuals with OHS also have lax skin and joints, bladder diverticula, inguinal hernias, and vascular tortuosity. Intellect is normal or slightly reduced. ATP7A-related DMN, an adult-onset disorder resembling Charcot-Marie-Tooth disease, shares none of the clinical or biochemical abnormalities characteristic of Menkes disease or OHS.","gard_id":"1521","name":"Menkes kinky-hair syndrome","content":"{\"Citation\":[{\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"3477514\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301586\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1413\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21487442\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0022716","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010651\"}","{\"db\":\"OMIM\",\"id\":\"309400\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"565\"}","{\"db\":\"OMIM\",\"id\":\"309400\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"MK\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"1521\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Menkes+disease/4603\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"59178007\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1413\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"309400\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["MK"],"keywords":[],"alternate_names":["Copper transport disease","Kinky hair disease","Menkea syndrome","Steely hair disease"],"type":"Disease","attribute_content":[],"symbol":"MNK","id":"2883"}
{"public_definition":"Kabuki syndrome (KS) is characterized by typical facial features (long palpebral fissures with eversion of the lateral third of the lower eyelid; arched and broad eyebrows; short columella with depressed nasal tip; large, prominent, or cupped ears), minor skeletal anomalies, persistence of fetal fingertip pads, mild-to-moderate intellectual disability, and postnatal growth deficiency. Other findings may include: congenital heart defects, genitourinary anomalies, cleft lip and/or palate, gastrointestinal anomalies including anal atresia, ptosis and strabismus, and widely spaced teeth and hypodontia. Functional differences can include: increased susceptibility to infections and autoimmune disorders, seizures, endocrinologic abnormalities (including isolated premature thelarche in females), feeding problems, and hearing loss.","name":"Kabuki syndrome 2","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21882399\",\"@Source\":\"PubMed\"},{\"$\":\"NBK62111\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C3275495","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010465\"}","{\"db\":\"OMIM\",\"id\":\"300867\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2322\"}","{\"db\":\"Genetic Alliance\",\"id\":\"KABUKI+SYNDROME+2/8701\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK62111\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300867\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":[],"type":"Disease","attribute_content":[],"symbol":"KABUK2","id":"16803"}
{"public_definition":"Kabuki syndrome (KS) is characterized by typical facial features (long palpebral fissures with eversion of the lateral third of the lower eyelid; arched and broad eyebrows; short columella with depressed nasal tip; large, prominent, or cupped ears), minor skeletal anomalies, persistence of fetal fingertip pads, mild-to-moderate intellectual disability, and postnatal growth deficiency. Other findings may include: congenital heart defects, genitourinary anomalies, cleft lip and/or palate, gastrointestinal anomalies including anal atresia, ptosis and strabismus, and widely spaced teeth and hypodontia. Functional differences can include: increased susceptibility to infections and autoimmune disorders, seizures, endocrinologic abnormalities (including isolated premature thelarche in females), feeding problems, and hearing loss.","name":"Kabuki syndrome 1","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21882399\",\"@Source\":\"PubMed\"},{\"$\":\"NBK62111\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"CN030661","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007843\"}","{\"db\":\"OMIM\",\"id\":\"147920\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2322\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK62111\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"147920\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":[],"type":"Disease","attribute_content":[],"symbol":"KABUK1","id":"1879"}
{"public_definition":"Kabuki syndrome (KS) is characterized by typical facial features (long palpebral fissures with eversion of the lateral third of the lower eyelid; arched and broad eyebrows; short columella with depressed nasal tip; large, prominent, or cupped ears), minor skeletal anomalies, persistence of fetal fingertip pads, mild-to-moderate intellectual disability, and postnatal growth deficiency. Other findings may include: congenital heart defects, genitourinary anomalies, cleft lip and/or palate, gastrointestinal anomalies including anal atresia, ptosis and strabismus, and widely spaced teeth and hypodontia. Functional differences can include: increased susceptibility to infections and autoimmune disorders, seizures, endocrinologic abnormalities (including isolated premature thelarche in females), feeding problems, and hearing loss.","gard_id":"6810","name":"Kabuki syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21882399\",\"@Source\":\"PubMed\"},{\"$\":\"NBK62111\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0796004","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0016512\"}","{\"db\":\"OMIM\",\"id\":\"PS147920\",\"type\":\"Phenotypic series\"}","{\"db\":\"Orphanet\",\"id\":\"2322\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Kabuki+syndrome/3945\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kabuki make-up syndrome\"}","{\"db\":\"SNOMED CT\",\"id\":\"313426007\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Kabuki make-up syndrome\"}","{\"db\":\"OMIM\",\"id\":\"147920\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"KMS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6810\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"PS147920 \",\"type\":\"Phenotypic series\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK62111\",\"ref_field\":\"public_definition\"}"],"alternate_symbols":["KMS","NKS"],"keywords":[],"alternate_names":["Kabuki make-up syndrome","Niikawa-Kuroki syndrome"],"type":"Disease","attribute_content":[],"id":"33104"}
{"public_definition":"The spectrum of propionic acidemia (PA) ranges from neonatal-onset to late-onset disease. Neonatal-onset PA, the most common form, is characterized by a healthy newborn with poor feeding and decreased arousal in the first few days of life, followed by progressive encephalopathy of unexplained origin. Without prompt diagnosis and management, this is followed by progressive encephalopathy manifesting as lethargy, seizures, or coma that can result in death. It is frequently accompanied by metabolic acidosis with anion gap, lactic acidosis, ketonuria, hypoglycemia, hyperammonemia, and cytopenias. Individuals with late-onset PA may remain asymptomatic and suffer a metabolic crisis under catabolic stress (e.g., illness, surgery, fasting) or may experience a more insidious onset with the development of multiorgan complications including vomiting, protein intolerance, failure to thrive, hypotonia, developmental delays or regression, movement disorders, or cardiomyopathy. Isolated cardiomyopathy can be observed on rare occasion in the absence of clinical metabolic decompensation or neurocognitive deficits. Manifestations of neonatal and late-onset PA over time can include growth impairment, intellectual disability, seizures, basal ganglia lesions, pancreatitis, and cardiomyopathy. Other rarely reported complications include optic atrophy, hearing loss, premature ovarian insufficiency, and chronic renal failure.","gard_id":"467","name":"Propionic acidemia","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"22593918\",\"@Source\":\"PubMed\"},{\"$\":\"NBK92946\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0268579","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003353\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011628\"}","{\"db\":\"OMIM\",\"id\":\"606054\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"35\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0003353\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Propionyl-CoA carboxylase deficiency\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"467\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Propionic+acidemia/5994\",\"ref_field\":\"name\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0011628\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK92946\",\"ref_field\":\"public_definition\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Glycinemia, ketotic","Hyperglycinemia with ketoacidosis and leukopenia","Ketotic hyperglycinemia","PCC deficiency","Propionyl-CoA carboxylase deficiency"],"type":"Disease","attribute_content":[],"symbol":"PROP","id":"5805"}
{"public_definition":"MIRAGE syndrome is an acronym for the major findings of myelodysplasia, infection, restriction of growth, adrenal hypoplasia, genital phenotypes, and enteropathy. Cytopenias are typically seen soon after birth; Thrombocytopenia is the most common followed by anemia and pancytopenia. Recurrent infections from early infancy include pneumonia, urinary tract infection, gastroenteritis, meningitis, otitis media, dermatitis, subcutaneous abscess, and sepsis. Reported genital phenotypes in those with 46,XY karyotype included hypospadias, microphallus, bifid shawl scrotum, ambiguous genitalia, or complete female genitalia. Hypoplastic or dysgenetic ovaries have been reported in females. Gastrointestinal complications include chronic diarrhea and esophageal dysfunction. Moderate-to-severe global developmental delay is reported in most affected individuals. Autonomic dysfunction and renal dysfunction are also reported.","gard_id":"13108","name":"Mirage syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"33237688\",\"@Source\":\"PubMed\"},{\"$\":\"NBK564655\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C4284088","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0014888\"}","{\"db\":\"OMIM\",\"id\":\"617053\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"494433\"}","{\"db\":\"OMIM\",\"id\":\"617053\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MYELODYSPLASIA, INFECTION, RESTRICTION OF GROWTH, ADRENAL HYPOPLASIA, GENITAL PHENOTYPES, AND ENTEROPATHY\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"13108\",\"ref_field\":\"gard_id\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK564655\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"617053\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["MYELODYSPLASIA, INFECTION, RESTRICTION OF GROWTH, ADRENAL HYPOPLASIA, GENITAL PHENOTYPES, AND ENTEROPATHY"],"type":"Disease","attribute_content":[],"symbol":"MIRAGE","id":"35847"}
{"public_definition":"COL1A1/2 osteogenesis imperfecta (COL1A1/2-OI) is characterized by fractures with minimal or absent trauma, variable dentinogenesis imperfecta (DI), and, in adult years, hearing loss. The clinical features of COL1A1/2-OI represent a continuum ranging from perinatal lethality to individuals with severe skeletal deformities, mobility impairments, and very short stature to nearly asymptomatic individuals with a mild predisposition to fractures, normal dentition, normal stature, and normal life span. Fractures can occur in any bone but are most common in the extremities. DI is characterized by gray or brown teeth that may appear translucent, wear down, and break easily. COL1A1/2-OI has been classified into four types based on clinical presentation and radiographic findings. This classification system can be helpful in providing information about prognosis and management for a given individual. The four more common OI types are now referred to as follows: Classic non-deforming OI with blue sclerae (previously OI type I). Perinatally lethal OI (previously OI type II). Progressively deforming OI (previously OI type III). Common variable OI with normal sclerae (previously OI type IV).","gard_id":"10142","name":"Osteogenesis imperfecta, recessive perinatal lethal","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301472\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1295\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EMQN, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3234509\",\"@Source\":\"pmc\"}}]}","medgen_id":"C0268358","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008147\"}","{\"db\":\"OMIM\",\"id\":\"166210\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"216804\"}","{\"db\":\"OMIM\",\"id\":\"166210\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OI, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0006\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0017\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0023\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0029\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0031\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0032\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0039\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0041\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0043\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0044\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0045\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0047\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0056\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0060\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0069\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0070\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120150.0073\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0007\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0008\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0009\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0010\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0011\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0015\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0016\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0018\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0019\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0022\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0029\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0034\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"120160.0053\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"166210\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"OSTEOGENESIS IMPERFECTA, TYPE II\"}","{\"db\":\"OMIM\",\"id\":\"166210\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"OIC\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10142\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Osteogenesis+imperfecta+type+2A/5456\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"86470003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1295\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"166210\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["COL1A1","OI2A","OIC"],"keywords":[],"alternate_names":["OI type 2A","OI type IIA","OI, TYPE II","OSTEOGENESIS IMPERFECTA, TYPE II","Osteogenesis Imperfecta Type IIA","Osteogenesis imperfecta congenita","Osteogenesis imperfecta congenita perinatal lethal form","Osteogenesis imperfecta type 2A","Vrolik type of osteogenesis imperfecta"],"type":"Disease","attribute_content":[],"symbol":"OI2","id":"3677"}
{"public_definition":"The spectrum of CDC73-related disorders includes the following phenotypes: Hyperparathyroidism-jaw tumor (HPT-JT) syndrome. Primary hyperparathyroidism, the main finding of HPT-JT syndrome, occurs in up to 95% of affected individuals; onset is typically in late adolescence or early adulthood. HPT-JT-associated primary hyperparathyroidism is usually caused by a single parathyroid adenoma. In approximately 10%-15% of individuals, primary hyperparathyroidism is caused by parathyroid carcinoma. Ossifying fibromas of the mandible or maxilla, also known as cementifying fibromas and cemento-ossifying fibromas, occur in 30%-40% of individuals with HPT-JT syndrome. Although benign, these tumors can be locally aggressive and may continue to enlarge if not treated. Approximately 20% of individuals with HPT-JT syndrome have kidney lesions, most commonly cysts; renal hamartomas and (more rarely) Wilms tumor have also been reported. Benign and malignant uterine tumors appear to be common in women with HPT-JT syndrome. Parathyroid carcinoma. Most parathyroid carcinomas are functional, resulting in hyperparathyroidism and a high serum calcium level; however, nonfunctioning parathyroid carcinomas are also rarely described in individuals with a CDC73-related disorder. A germline CDC73 pathogenic variant has been identified in 20%-29% of individuals with apparently sporadic parathyroid carcinoma. Familial isolated hyperparathyroidism (FIHP). FIHP is characterized by primary hyperparathyroidism without other associated syndromic features. Individuals with CDC73-related FIHP tend to have a more severe clinical presentation and younger age of onset than individuals with FIHP in whom a CDC73 pathogenic variant has not been identified.","gard_id":"7329","name":"Parathyroid carcinoma","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301744\",\"@Source\":\"PubMed\"},{\"$\":\"NBK3789\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0687150","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006780\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0012004\"}","{\"db\":\"OMIM\",\"id\":\"608266\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"143\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"7329\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Parathyroid+carcinoma/5598\",\"ref_field\":\"name\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0006780\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"255037004\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK3789\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"608266\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["CDC73-Related Parathyroid Carcinoma","Parathyroid cancer"],"type":"Disease","attribute_content":[],"symbol":"PRTC","id":"3270"}
{"public_definition":"C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis (C9orf72-FTD/ALS) is characterized most often by frontotemporal dementia (FTD) and upper and lower motor neuron disease (MND); however, atypical presentations also occur. Age at onset is usually between 50 and 64 years (range: 20-91 years) irrespective of the presenting manifestations, which may be pure FTD, pure amyotrophic lateral sclerosis (ALS), or a combination of the two phenotypes. The clinical presentation is highly heterogeneous and may differ between and within families, causing an unpredictable pattern and age of onset of clinical manifestations. The presence of MND correlates with an earlier age of onset and a worse overall prognosis.","name":"Amyotrophic lateral sclerosis and/or frontotemporal dementia 1","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301623\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1450\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"25577942\",\"@Source\":\"PubMed\"},{\"$\":\"NBK268647\",\"@Source\":\"BookShelf\"}]}]}","medgen_id":"C3888102","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0007105\"}","{\"db\":\"OMIM\",\"id\":\"105550\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"275872\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0007105\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Frontotemporal dementia with motor neuron disease 1\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501377\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"FTDALS\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK268647\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"105550\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["FTDALS"],"keywords":[],"alternate_names":["Frontotemporal dementia with motor neuron disease 1"],"type":"Disease","attribute_content":[],"symbol":"FTDALS1","id":"1898"}
{"public_definition":"The NSDHL-related disorders include: CHILD (congenital hemidysplasia with ichthyosiform nevus and limb defects) syndrome, an X-linked condition that is usually male lethal during gestation and thus predominantly affects females; and CK syndrome, an X-linked disorder that affects males. CHILD syndrome is characterized by unilateral distribution of ichthyosiform (yellow scaly) skin lesions and ipsilateral limb defects that range from shortening of the metacarpals and phalanges to absence of the entire limb. Intellect is usually normal. The ichthyosiform skin lesions are usually present at birth or in the first weeks of life; new lesions can develop in later life. Nail changes are also common. The heart, lung, and kidneys can also be involved. CK syndrome (named for the initials of the original proband) is characterized by mild to severe cognitive impairment and behavior problems (aggression, attention deficit hyperactivity disorder, and irritability). All affected males reported have developed seizures in infancy and have cerebral cortical malformations and microcephaly. All have distinctive facial features, a thin habitus, and relatively long, thin fingers and toes. Some have scoliosis and kyphosis. Strabismus is common. Optic atrophy is also reported.","name":"CK syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"21290788\",\"@Source\":\"PubMed\"},{\"$\":\"NBK51754\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C3151781","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010441\"}","{\"db\":\"OMIM\",\"id\":\"300831\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"251383\"}","{\"db\":\"OMIM\",\"id\":\"300831\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, WITH THIN BODY HABITUS AND CORTICAL MALFORMATION\"}","{\"db\":\"Genetic Alliance\",\"id\":\"NSDHL-Related+Disorders/9023\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"NSDHL-Related Disorders\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010441\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK51754\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300831\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["MENTAL RETARDATION, X-LINKED, WITH THIN BODY HABITUS AND CORTICAL MALFORMATION","NSDHL-Related Disorders"],"type":"Disease","attribute_content":[],"symbol":"CKS","id":"15758"}
{"name":"Cerebral folate transport deficiency","content":"{\"Citation\":{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}}}","medgen_id":"C2751584","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013110\"}","{\"db\":\"OMIM\",\"id\":\"613068\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"217382\"}","{\"db\":\"OMIM\",\"id\":\"136430.0004\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FOLATE RECEPTOR DEFICIENCY\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000512432\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520979\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520980\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520995\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520996\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520997\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000551668\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552397\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000559496\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"SNOMED CT\",\"id\":\"711403001\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"613068\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Cerebral folate deficiency syndrome","FOLATE RECEPTOR DEFICIENCY","Neurodegeneration due to cerebral folate transport deficiency"],"type":"Disease","attribute_content":[],"disease_mechanism_id":"273","symbol":"NCFTD","id":"6808","disease_mechanism":"loss of function"}
{"public_definition":"Beta-thalassemia (ß-thalassemia) is characterized by reduced synthesis of the hemoglobin subunit beta (hemoglobin beta chain) that results in microcytic hypochromic anemia, an abnormal peripheral blood smear with nucleated red blood cells, and reduced amounts of hemoglobin A (HbA) on hemoglobin analysis. Individuals with thalassemia major have severe anemia and hepatosplenomegaly; they usually come to medical attention within the first two years of life. Without treatment, affected children have severe failure to thrive and shortened life expectancy. Treatment with a regular transfusion program and chelation therapy, aimed at reducing transfusion iron overload, allows for normal growth and development and may improve the overall prognosis. Individuals with thalassemia intermedia present later and have milder anemia that does not require regular treatment with blood transfusion. These individuals are at risk for iron overload secondary to increased intestinal absorption of iron as a result of ineffective erythropoiesis.","name":"beta Thalassemia","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301599\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1426\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACOG, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"8735302\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0005283","xrefs":["{\"db\":\"OMIM\",\"id\":\"613985\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"848\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260581\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501386\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501908\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501909\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508856\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000515560\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520044\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520115\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521590\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529085\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556525\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556526\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558937\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000567333\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570317\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592286\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592287\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Beta+Thalassemia/814\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"65959000\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1426\",\"ref_field\":\"public_definition\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Cooley's anemia","Erythroblastic anemia","Mediterranean anemia"],"type":"Disease","attribute_content":[],"disease_mechanism_id":"273","symbol":"BTHAL","id":"11970","disease_mechanism":"loss of function"}
{"public_definition":"FMR1 disorders include fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency (FXPOI). Fragile X syndrome occurs in individuals with an FMR1 full mutation or other loss-of-function variant and is nearly always characterized in affected males by developmental delay and intellectual disability along with a variety of behavioral issues. Autism spectrum disorder is present in 50%-70% of individuals with FXS. Affected males may have characteristic craniofacial features (which become more obvious with age) and medical problems including hypotonia, gastroesophageal reflux, strabismus, seizures, sleep disorders, joint laxity, pes planus, scoliosis, and recurrent otitis media. Adults may have mitral valve prolapse or aortic root dilatation. The physical and behavioral features seen in males with FXS have been reported in females heterozygous for the FMR1 full mutation, but with lower frequency and milder involvement. FXTAS occurs in individuals who have an FMR1 premutation and is characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment. Psychiatric disorders are common. Age of onset is typically between 60 and 65 years and is more common among males who are hemizygous for the premutation (40%) than among females who are heterozygous for the premutation (16%-20%). FXPOI, defined as hypergonadotropic hypogonadism before age 40 years, has been observed in 20% of women who carry a premutation allele compared to 1% in the general population.","gard_id":"6464","name":"Fragile X syndrome","content":"{\"Citation\":[{\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22797890\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301558\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1384\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACMG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110344\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111012\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110946\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3111547\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21540884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23519317\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"EMQN, 2015\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25227148\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23765048\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0016667","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010383\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"449291\"}","{\"db\":\"Orphanet\",\"id\":\"908\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"FRAGILE X MENTAL RETARDATION SYNDROME\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000264966\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000552393\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000553203\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556541\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558914\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560955\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000561923\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568029\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568236\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568277\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569189\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569426\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569960\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000571198\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000576178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592286\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592287\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592290\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6464\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fragile+X+Syndrome/2906\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"613003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1384\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"300624\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["FRAGILE X MENTAL RETARDATION SYNDROME","Fra(X) syndrome","Fragile X syndrome, type A","MENTAL RETARDATION, X-LINKED, ASSOCIATED WITH marXq28","Marker X syndrome","Martin-Bell syndrome","X-linked mental retardation and macroorchidism"],"type":"Disease","attribute_content":[],"disease_mechanism_id":"273","symbol":"FXS","id":"1302","disease_mechanism":"loss of function"}
{"public_definition":"The FLNB disorders include a spectrum of phenotypes ranging from mild to severe. At the mild end are spondylocarpotarsal synostosis (SCT) syndrome and Larsen syndrome; at the severe end are the phenotypic continuum of atelosteogenesis types I (AOI) and III (AOIII) and Piepkorn osteochondrodysplasia (POCD). SCT syndrome is characterized by postnatal disproportionate short stature, scoliosis and lordosis, clubfeet, hearing loss, dental enamel hypoplasia, carpal and tarsal synostosis, and vertebral fusions. Larsen syndrome is characterized by congenital dislocations of the hip, knee, and elbow; clubfeet (equinovarus or equinovalgus foot deformities); scoliosis and cervical kyphosis, which can be associated with a cervical myelopathy; short, broad, spatulate distal phalanges; distinctive craniofacies (prominent forehead, depressed nasal bridge, malar flattening, and widely spaced eyes); vertebral anomalies; and supernumerary carpal and tarsal bone ossification centers. Individuals with SCT syndrome and Larsen syndrome can have midline cleft palate and hearing loss. AOI and AOIII are characterized by severe short-limbed dwarfism; dislocated hips, knees, and elbows; and clubfeet. AOI is lethal in the perinatal period. In individuals with AOIII, survival beyond the neonatal period is possible with intensive and invasive respiratory support. Piepkorn osteochondrodysplasia (POCD) is a perinatal-lethal micromelic dwarfism characterized by flipper-like limbs (polysyndactyly with complete syndactyly of all fingers and toes, hypoplastic or absent first digits, and duplicated intermediate and distal phalanges), macrobrachycephaly, prominant forehead, hypertelorism, and exophthalmos. Occasional features include cleft palate, omphalocele, and cardiac and genitourinary anomalies. The radiographic features at mid-gestation are characteristic.","name":"Larsen syndrome","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301736\",\"@Source\":\"PubMed\"},{\"$\":\"NBK2534\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0175778","xrefs":["{\"db\":\"OMIM\",\"id\":\"150250\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"503\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome%2C+dominant+type/4094\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Larsen syndrome, dominant type\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508858\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522271\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522272\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Larsen+syndrome/4093\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"larsen-syndrome\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"63387002\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK2534\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"150250\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":["LRS1"],"keywords":[],"alternate_names":["Bilateral dislocation of the knees, pes cavus, cylindrically shaped fingers and characteristic facies","Larsen syndrome, dominant type"],"type":"Disease","attribute_content":["{\"Attribute\":{\"$\":\"Larsen syndrome is a disorder that affects the development of bones throughout the body. The signs and symptoms of Larsen syndrome vary widely even within the same family. Affected individuals are usually born with dislocations of the hips, knees, or elbows. Foot abnormalities, such as inward- and upward-turning feet (clubfeet), are also common. Affected individuals generally have small extra bones in their wrists and ankles that are visible on x-ray images. The tips of their fingers, especially the thumbs, are typically blunt and square-shaped (spatulate).Characteristic facial features in people with Larsen syndrome include a prominent forehead (frontal bossing), flattening of the bridge of the nose and middle of the face (midface hypoplasia), and wide-set eyes (ocular hypertelorism). Many people with Larsen syndrome have an opening in the roof of the mouth (a cleft palate). Affected individuals may also have hearing loss caused by malformations in tiny bones in the ears (ossicles).Short stature is a common feature of Larsen syndrome. In addition, people with the condition may have an unusually large range of joint movement (hypermobility) or joint deformities (contractures) that restrict movement. People with Larsen syndrome can also have abnormal curvature of the spine (kyphosis or scoliosis) that can impair breathing or compress the spinal cord and lead to weakness of the limbs. Some affected individuals experience respiratory problems, such as partial closing of the airways, short pauses in breathing (apnea), and frequent respiratory infections. Heart and kidney problems can also occur in people with Larsen syndrome. People with this condition can survive into adulthood. Their intellectual function is usually unaffected.\",\"@Type\":\"public definition\"},\"XRef\":{\"@DB\":\"Genetics Home Reference\",\"@ID\":\"larsen-syndrome\"}}"],"disease_mechanism_id":"273","symbol":"LRS","id":"14587","disease_mechanism":"loss of function"}
{"public_definition":"Phenylalanine hydroxylase (PAH) deficiency results in intolerance to the dietary intake of the essential amino acid phenylalanine and produces a spectrum of disorders. The risk of adverse outcome varies based on the degree of PAH deficiency. Without effective therapy, most individuals with severe PAH deficiency, known as classic PKU, develop profound and irreversible intellectual disability. Affected individuals on an unrestricted diet who have phenylalanine levels above normal but below 1,200 µmol/L (20 mg/dL) are at much lower risk for impaired cognitive development in the absence of treatment.","name":"Phenylketonuria","content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301677\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1504\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"USPSTF, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2267416\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGenetest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21915151\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24385074\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2014\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"3918542\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"Camp et al., 2014\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"24667081\",\"@Source\":\"PubMed\"}}]}","medgen_id":"C0751434","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009861\"}","{\"db\":\"OMIM\",\"id\":\"261600\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"716\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000260641\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330994\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505064\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000505124\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000506557\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507953\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529111\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000560957\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592287\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Phenylketonuria/5714\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"154735006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1504\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"261600\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Classic phenylketonuria","Folling disease","Oligophrenia phenylpyruvica","Phenylketonurias"],"type":"Disease","attribute_content":[],"disease_mechanism_id":"273","symbol":"PKU","id":"3795","disease_mechanism":"loss of function"}
{"public_definition":"Cystic fibrosis (CF) is a multisystem disease affecting epithelia of the respiratory tract, exocrine pancreas, intestine, hepatobiliary system, and exocrine sweat glands. Morbidities include progressive obstructive lung disease with bronchiectasis, frequent hospitalizations for pulmonary disease, pancreatic insufficiency and malnutrition, recurrent sinusitis and bronchitis, and male infertility. Pulmonary disease is the major cause of morbidity and mortality in CF. Meconium ileus occurs at birth in 15%-20% of newborns with CF. More than 95% of males with CF are infertile. Congenital absence of the vas deferens (CAVD) is generally identified during evaluation of infertility or as an incidental finding at the time of a surgical procedure. Hypoplasia or aplasia of the vas deferens and seminal vesicles may occur either bilaterally or unilaterally. Testicular development and function and spermatogenesis are usually normal.","gard_id":"6233","name":"Cystic fibrosis","content":"{\"Citation\":[{\"@Abbrev\":\"ACMG/ACOG, 2001\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"11280952\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2004\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110945\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301428\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1250\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"ACOG, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19888064\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2005\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"15789152\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2008\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"3110977\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"CPGPT/CF FPT Committees, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20675678\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ECFS, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20605539\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19914445\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2009\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"19914443\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG ACT Sheets, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21938795\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG Lab QA, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12394352\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CDC, 2012\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"22475884\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Accurso et al., 2010\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"3148255\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"ACOG, 2011\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"21422883\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CPIC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"4026598\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"NSGC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"24014130\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"HGS Australasia, 2014\",\"@Type\":\"Position Statement\",\"ID\":{\"$\":\"25431289\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Wainwright et al., 2015\",\"@Type\":\"Suggested Reading\",\"ID\":{\"$\":\"25981758\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"CFF, 2007\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"17761616\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"DailyMed Drug Label, 2012\",\"@Type\":\"practice guideline\",\"CitationText\":{\"$\":\"DailyMed Drug Label, KALYDECO, 2012\"},\"URL\":{\"$\":\"https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0ab0c9f8-3eee-4e0f-9f3f-c1e16aaffe25\"}}]}","medgen_id":"C0010674","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009061\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"586\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000004176\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000005248\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000025280\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000028916\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000074114\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000209428\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000226639\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000246717\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000277984\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000320929\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000328569\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000330969\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000332363\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501120\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501918\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501920\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000501921\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507003\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507006\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507864\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000507950\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508782\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508810\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508811\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508812\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508889\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508890\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508893\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000508894\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000514611\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000520059\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000521905\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000522527\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000528606\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000529460\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000530118\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556535\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000556536\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558875\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000558928\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000568279\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569406\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569426\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569602\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569639\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569790\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569791\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569946\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569960\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569982\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569983\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570010\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570019\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570054\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000570317\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000571198\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000576178\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592286\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592287\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592290\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6233\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Cystic+Fibrosis/2071\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190905008\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1250\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"219700\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Mucoviscidosis"],"type":"Disease","attribute_content":[],"disease_mechanism_id":"273","symbol":"CF","id":"1695","disease_mechanism":"loss of function"}
{"public_definition":"The term \"galactosemia\" refers to disorders of galactose metabolism that include classic galactosemia, clinical variant galactosemia, and biochemical variant galactosemia. This GeneReview focuses on: Classic galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage, bleeding, and E coli sepsis in untreated infants. If a lactose-restricted diet is provided during the first ten days of life, the neonatal signs usually quickly resolve and the complications of liver failure, sepsis, and neonatal death are prevented; however, despite adequate treatment from an early age, children with classic galactosemia remain at increased risk for developmental delays, speech problems (termed childhood apraxia of speech and dysarthria), and abnormalities of motor function. Almost all females with classic galactosemia manifest premature ovarian insufficiency (POI). Clinical variant galactosemia, which can result in life-threatening complications including feeding problems, failure to thrive, hepatocellular damage including cirrhosis, and bleeding in untreated infants. This is exemplified by the disease that occurs in African Americans and native Africans in South Africa. Persons with clinical variant galactosemia may be missed with newborn screening (NBS) as the hypergalactosemia is not as marked as in classic galactosemia and breath testing is normal. If a lactose-restricted diet is provided during the first ten days of life, the severe acute neonatal complications are usually prevented. African Americans with clinical variant galactosemia and adequate early treatment do not appear to be at risk for long-term complications including POI.","gard_id":"2424","name":"Galactosemia","content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301691\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1518\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0016952","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004919\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0018116\"}","{\"db\":\"Orphanet\",\"id\":\"352\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0004919\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Galactose intolerance\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000569081\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000591986\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592259\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592287\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000592289\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"2424\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Galactosemia/2973\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"190745006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1518\",\"ref_field\":\"public_definition\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Galactose intolerance"],"type":"Disease","attribute_content":[],"disease_mechanism_id":"273","id":"16954","disease_mechanism":"loss of function"}
{"public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","gard_id":"6400","name":"Fabry disease","content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C0002986","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"alternate_symbols":[],"keywords":[],"alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"type":"Disease","attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"}]}"],"id":"1790","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A."}
